ACSoMP was established in 2003 to provide advice to WHO, including its Collaborating Centre for International Drug Monitoring (the UMC), and through it to the Member States of WHO, on safety issues relating to medicinal products. It guides WHO on general and specific issues related to Pharmacovigilance (PV). The Committee is composed of 12 members drawn from the WHO Expert Advisory Panels for Drug Evaluation and for Drug Policies and Management and, where appropriate, in consultation with other relevant WHO clusters and expert advisory panels. ACSoMP meets once a year to discuss ongoing and new pharmacovigilance topics, with particular focus on issues related to public health programmes.
ACSoMP composition
ACSoMP recommendations
ACSoMP COVID-19 Theurapeutics Sub-Comittee
The ACSoMP COVID-19 Sub-Committee will review, evaluate, and interpret post-introduction COVID-19 medicine safety data from different countries. The review will also include data from ongoing clinical studies and / or other observational studies when these are completed. Based on its review, the sub-Committee will advise WHO on the overall safety of COVID-19 medicines, additional monitoring and/or risk mitigation needs and, when required, on public communication of safety information. More